Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP – Get Free Report) saw a large increase in short interest in the month of April. As of April 15th, there was short interest totalling 174,300 shares, an increase of 61.8% from the March 31st total of 107,700 shares. Based on an average daily volume of 257,400 shares, the short-interest ratio is presently 0.7 days. Approximately 0.7% of the company’s shares are sold short.
Coeptis Therapeutics Stock Up 4.0 %
Shares of NASDAQ:COEP opened at $0.33 on Friday. Coeptis Therapeutics has a 1 year low of $0.29 and a 1 year high of $2.19. The company has a market cap of $12.08 million, a PE ratio of -0.40 and a beta of -0.89. The company has a debt-to-equity ratio of 0.03, a current ratio of 1.76 and a quick ratio of 1.76. The stock’s 50-day moving average is $0.40 and its 200 day moving average is $0.73.
Coeptis Therapeutics (NASDAQ:COEP – Get Free Report) last announced its quarterly earnings results on Monday, March 25th. The company reported ($0.08) earnings per share (EPS) for the quarter. Sell-side analysts anticipate that Coeptis Therapeutics will post -0.77 EPS for the current year.
Institutional Inflows and Outflows
About Coeptis Therapeutics
Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.
See Also
- Five stocks we like better than Coeptis Therapeutics
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- 3 Stocks Leading the U.S. Agriculture Comeback
- Why Invest in 5G? How to Invest in 5G Stocks
- How to Use Put Debit Spreads to Profit From Falling Stocks
- What is the FTSE 100 index?
- Alphabet Changes the Narrative with Its First-Ever Dividend
Receive News & Ratings for Coeptis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coeptis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.